Combination chemotherapy with XXXX , @entity632 , @entity1891 (VAP) in @entity0 . A phase II study.

@entity632 @entity1 @entity1665 @entity137 @entity42870 @entity0 @entity440 @entity390 @entity786 @entity1891 @entity1431 @entity1499 @entity1487
The purpose of this study was to evaluate VAP combination chemotherapy in @entity0 : @entity42870 80 mg/m2 p.o. days 1-5, @entity632 40 mg/m2 and @entity1891 1.4 mg/m2 1st day in cycles of 3 weeks. Twenty-one @entity1 entered the study and 19 were evaluable. The mean age was 54.5 years (25-69) with an average performance status of 60 according to Karnofsky. Hormonal receptors were unknown in 10, positive in 6 and negative in 3. The dominant site of disease was soft tissues in 11, bones in 1, liver in 3 and lung in 4. Fourteen @entity1 had as prior treatment @entity786 , @entity1499 and @entity1487 (CMF), two had @entity440 and three none. Ten @entity1 (52.6%) had a partial response with a mean survival of 7.8+ months, 5 @entity1 (26.3%) had stable disease with a mean survival 6.6+ months and 4 @entity1 (21.1%) had progressive disease with a mean survival of 3 months. Regarding @entity137 all @entity1 had @entity1665 , most of the @entity1 had @entity390 grade I, whereas 5 @entity1 developed mild @entity1431 . We conclude that VAP is an effective, well tolerated chemotherapy combination in @entity1 with @entity0 which deserves further clinical trials.
